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Abstract 
Objective: Patients with coronary artery disease (CAD) often have prior stroke or concomitant 
extracardiac vascular disease (EVD) such as cerebral, aortic, or peripheral vascular disease. However, 
clinical outcomes after coronary revascularization in patients with polyvascular disease have not 
been fully elucidated. 
Methods: Among 15263 patients undergoing first coronary revascularization enrolled in the 
CREDO-Kyoto registry Cohort-2 from January 2005 to December 2007, there were 1443 patients 
with prior stroke (stroke+CAD group), 974 patients with EVD (EVD+CAD group), 253 patients with 
both prior stroke and EVD (stroke/EVD/CAD group) and 12593 patients with neither prior stroke 
nor EVD (CAD alone group [reference]).  
Results: The cumulative incidence of major adverse cardiovascular events (MACE: composite of 
cardiovascular death, myocardial infarction and stroke) through 3 years was significantly higher in 
patients with polyvascular disease compared with reference patients (19.9% in the stroke+CAD 
group, 18.5% in the EVD+CAD group, 20.1% in the stroke/EVD/CAD group, and 11.2% in the 
CAD alone group, P<0.0001). After adjusting confounders, the presence of EVD and/or stroke was 
independently associated with higher risk for MACE compared with the reference group (adjusted 
HR [95%CI]: 1.34 [1.17-1.54], P<0.0001 in the stroke+CAD group, 1.56 [1.32-1.84], P<0.0001 in 
the EVD+CAD group, and 1.66 [1.24-2.23], P=0.0007 in the stroke/EVD/CAD group). However, the 
presence of EVD and/or stroke was not associated with higher risk for myocardial infarction. 
Conclusions: Clinical outcome after coronary revascularization was worse in patients with prior 
stroke and/or EVD, which was mainly driven by the increased risk for non-coronary cardiovascular 
events.  
 
Key words: peripheral vascular disease, stroke, coronary artery disease, coronary stent, coronary 
artery bypass grafting 
1. Introduction 
Patients with coronary artery disease (CAD) often have prior stroke or concomitant cerebral, 
aortic or peripheral vascular disease. The presence of cerebrovascular disease is associated with 
higher prevalence of CAD [1-2]. The prevalence of CAD is also reported to be high in patients with 
aortic aneurysm [3-4]. It is also reported that asymptomatic CAD was found in 25% of the patients 
undergoing carotid endarterectomy [5]. Furthermore, peripheral artery disease (PAD) could be a 
marker for atherosclerotic involvement of the coronary arteries [1,6]. 
The Reduction of Atherothrombosis for Continued Health (REACH) registry is one of the 
largest international epidemiologic database for atherothrombotic disease [7]. This registry showed 
that patients with prior history of ischemic events at baseline had the highest rate of subsequent 
ischemic events [8]. Furthermore, patients with polyvascular disease were associated with higher risk 
for cardiovascular events. However, clinical outcomes after coronary revascularization in patients 
with polyvascular disease have not been fully elucidated, especially in patients with stable CAD 
[9-11]. In the current study, we analyzed the impact of prior stroke or extra-cardiac vascular disease 
(EVD) on cardiovascular outcomes in a large Japanese observational database of patients who 
underwent first coronary revascularization. 
 
2. Methods 
2.1. Study population 
The CREDO-Kyoto (Coronary REvascularization Demonstrating Outcome study in Kyoto) 
percutaneous coronary intervention (PCI)/coronary artery bypass grafting (CABG) registry cohort-2 
is a multi-center registry enrolling consecutive patients undergoing first coronary revascularization 
procedures among 26 centers in Japan between January 2005 and December 2007 (Supplemental 
Appendix A). The relevant review boards or ethics committees in all participating centers approved 
the research protocol. This strategy is concordant with the guidelines for epidemiological studies 
issued by the Ministry of Health, Labor and Welfare of Japan. 
The design and patient enrollment of the CREDO-Kyoto PCI/CABG registry cohort-2 has 
been described previously [12].
 
A total of 15939 patients underwent PCI or CABG as the first 
coronary revascularization procedure during the 3 years of enrollment period. Excluding 67 patients 
who refused study participation, and 609 patients who underwent combined non-coronary surgery, 
15263 patients (PCI: 13087, and isolated CABG: 2176) constituted the study population for the 
current analyses. Patients were divided into 4 groups according to the presence of prior stroke or 
EVD: 1443 patients with prior stroke (stroke+CAD group), 974 patients with EVD (EVD+CAD 
group), 253 patients with both prior stroke and EVD (stroke/EVD/CAD group) and 12593 patients 
with neither prior stroke nor EVD (CAD alone group [reference]). Among 1227 patients with EVD, 
427 patients, 187 patients, and 702 patients had aortic disease, carotid artery disease and other 
peripheral vascular disease, either alone or in combination, respectively. 
 
2.2. Definitions 
 Definitions of baseline clinical characteristics were described previously [12]. Prior stroke 
included both ischemic and hemorrhagic stroke and was defined as stroke with neurological 
symptoms lasting >24 hours. Therefore, transient ischemic attack was excluded from the prior stroke. 
EVD was regarded to be present when aortic, carotid, or other peripheral vascular disease such as 
iliac, femoral, popliteal, tibioperoneal, or renal artery disease were being treated or scheduled for 
surgical or endovascular interventions. Patients with medical treatment only were excluded. The 
primary outcome measure in the current analysis was major adverse cardiovascular events (MACE; a 
composite of cardiovascular death, myocardial infarction (MI), or stroke).  
 
2.3. Data collection and follow-up 
  Demographic, angiographic, and procedural data were collected from hospital charts or 
databases according to pre-specified definitions by experienced clinical research coordinators in the 
independent research organization (Research Institute for Production Development, Kyoto, Japan) 
(Supplemental Appendix B). Follow-up data were obtained from hospital charts or by contacting 
patients, or referring physicians. Death, MI and stroke were adjudicated against original source 
documents by a clinical event committee (Supplemental Appendix C). Median follow-up duration 
was 946 (inter-quartile range: 675-1239) days. Two-year follow up was completed in 11891 patients 
(78%). 
 2.4. Statistical analysis 
 Variables were compared with analysis of variance. Continuous variables were expressed as 
mean value ± standard deviation. Cumulative incidence was estimated by the Kaplan-Meier method 
and differences were assessed with the log-rank test. 
 The adjusted risk for clinical outcomes was estimated by the Cox proportional hazard model 
by incorporating the presence of prior stroke, EVD and both of them together with the 32 clinically 
relevant factors shown in Table 1 as the risk adjusting variables to be consistent with our previous 
reports [12-13]. The continuous variables were dichotomized by clinically meaningful reference 
values or median values. Twenty-six centers were included in the model as stratification variables. In 
the Cox proportional hazard model, we developed dummy codes for presence of prior stroke, EVD 
and both of them with absence of prior stroke and EVD as the reference. The effect of each category 
compared to the reference category was expressed as hazard ratios (HR) and their 95% confidence 
intervals (CI).  
Statistical analyses were conducted by two physicians (Morikami Y and Natsuaki M) and by 
a statistician (Morimoto T) with the use of JMP 8.0 (SAS Institute Inc, Cary, NC) and SAS 9.2 (SAS 
Institute Inc, Cary, NC) softwares. All the statistical analyses were two-tailed. P values <0.05 were 
considered statistically significant. 
 
3. Results 
3.1. Baseline characteristics 
Because of the large sample size of the study, significant differences were observed in many 
baseline variables among the 4 groups. As compared with those patients with CAD alone, patients 
with EVD and/or stroke were the older and had lower body mass index. It is of note that prevalence 
of atrial fibrillation was higher in patients with prior stroke. Male gender, hypertension, diabetes, 
multivessel disease, unprotected left main coronary artery disease, target of chronic total occlusion, 
revascularization by CABG, chronic kidney disease, dialysis, anemia and malignancy were more 
prevalent in patients with EVD and/or stroke. In contrast, acute MI was more prevalent in patients 
with CAD alone. Statins, beta-blockers and thienopyridine were less frequently prescribed in patients 
with EVD and/or stroke, while calcium channel blockers, warfarin and proton pump inhibitors were 
more often used in patients with EVD and/or stroke (Table 1). 
 
3.2. Clinical outcomes  
Through 3-year follow-up, the cumulative incidence of MACE was significantly higher in 
patients with EVD and/or stroke as compared with patients with CAD alone (Table 2 and Figure 1). 
The cumulative incidences of all-cause death, cardiovascular death, non-cardiovascular death and 
stroke (both ischemic and hemorrhagic stroke) were also significantly higher in patients with EVD 
and/or stroke as compared with patients with CAD alone (Table 2 and Figure 1). Regarding oral 
 
anticoagulant therapy, the cumulative incidence of hemorrhagic stroke tended to be higher in those 
patients receiving oral anticoagulant therapy at time of hospital discharge as compared with those not 
receiving it. The cumulative incidence of hemorrhagic stroke was significantly higher in patients 
with prior stroke and/or EVD than in patients with CAD alone regardless of the use of oral 
anticoagulant therapy (Supplemental Table). Regarding oral antiplatelet therapy, the cumulative 
incidence of hemorrhagic stroke was significantly higher in those with prior stroke and/or EVD than 
in those with CAD alone in patients receiving dual antiplatelet therapy at discharge (Supplemental 
Table). On the other hand, the cumulative incidence of MI was not significantly different across the 4 
groups (Table 2). After adjusting confounders by multivariable analysis, the adjusted risks for MACE, 
all-cause death, non-cardiovascular death and stroke remained significantly higher in patients with 
EVD and/or stroke as compared with patients with CAD alone (Figure 2). In contrast, the adjusted 
risk of the 3 groups with EVD and/or stroke relative to the CAD alone group was neutral for MI and 
any coronary revascularization (Figure 2).  
Regarding the causes of death during follow-up, cardiac death was the most frequent cause 
of death in each group. Vascular death was more often found in patients with EVD and/or stroke as 
compared with patients with CAD alone. There was no significant difference in the proportion of 




The main findings of the current study are as follows: (1) Clinical outcome after coronary 
revascularization was worse in patients with prior stroke and/or EVD, which was mainly driven by 
the increased risk for non-coronary cardiovascular events; (2) However, the presence of EVD and/or 
stroke was not associated with higher risk for myocardial infarction. 
In the current study, patients with EVD were found in 1227 patients (8%) including 253 
patients with concomitant prior stroke. Presence of EVD has been reported to be an independent risk 
factor of long-term mortality in patients with CAD [14-16]. In consistent with these reports, 
coexistence of EVD with CAD was associated with higher risk for MACE, all-cause death, 
cardiovascular death, non-cardiovascular death and stroke after coronary revascularization in the 
current study.  
In this study, 1696 patients (11%) had prior stroke including 253 patients with concomitant 
EVD. The presence of prior stroke was associated with higher risk for MACE, all-cause death, 
non-cardiovascular death and stroke after coronary revascularization. In consistent with our report, 
Mukherjee et al reported that patients with prior stroke had worse cardiovascular outcomes after 
acute coronary syndrome [10]. It is interesting to note that prevalence of atrial fibrillation was higher 
in patients with prior stroke in the current study. Significant proportion of prior and/or recurrent 
stroke might be embolic stroke related to atrial fibrillation. Systemic atherosclerotic burden in the 
stroke population might be less extensive as compared with that in the EVD population, leading to 
relatively lower excess risk of the stroke population compared to the EVD population. 
Cumulative incidences of MACE, all-cause death, cardiovascular death, non-cardiovascular 
death and stroke were significantly higher in the stroke/EVD/CAD group compared with the CAD 
alone group, while those were generally similar across the 3 groups of patients with EVD and/or 
stroke. However, multivariate analysis showed that the risks for those outcomes were highest in 
patients with both prior stroke and EVD. These findings are consistent with previous reports. 
Mukherjee et al reported that the risk for death/MI/stroke was the highest in patients with PAD and 
prior stroke compared with those with either PAD or stroke [10]. Subherwal et al reported the impact 
of PAD and cerebrovascular disease (CVD) on long-term cardiovascular outcomes in patients with 
non-ST-segment elevation MI [17]. AS compared with the CAD alone group, patients with 
involvement of all 3 arterial beds had the highest risk for long-term mortality. These findings suggest 
that cardiovascular risk seems to be related to the number of arterial territories with significant 
atherosclerosis. 
In the REACH registry, patients with polyvascular disease had significantly higher risk for 
cardiovascular events compared with those with risk factors only [8]. Furthermore, prior stoke was 
associated with higher risk for death, MI, or stroke, including both ischemic and hemorrhagic stroke 
in patients with coronary artery disease [18]. Despite greater prevalence of multivessel coronary 
artery disease, patients with prior stroke and/or EVD did not have excess risk for MI as compared 
with patients with CAD alone, while the risk for stroke was significantly higher in patients with prior 
stroke and/or EVD than in patients with CAD alone in this study. Cumulative incidences of both 
cerebral infarction and cerebral hemorrhage were also significantly higher in patients with prior 
stroke and/or EVD than in patients with CAD alone. Therefore, the worse cardiovascular outcome in 
patients with prior stroke and/or EVD was mainly driven by the increased risk for non-coronary 
cardiovascular events. Lower incidence of MI relative to stroke in Japanese population might be one 
of the reasons for these results [19-20]. More liberal use of CABG as the mode of coronary 
revascularization might contribute to the prevention of MI in patients with prior stroke and/or EVD.  
        Despite higher risk for cardiovascular events, higher mortality in particular, in patients 
with polyvascular disease, several studies have highlited that relatively little attention had been paid 
in the detection of PAD [21-22].  measurement identifies a large number of 
patients with previously unrecognized PAD. Ultrasonography is also a noninvasive examination and 
considered to be an effective method to detect the abdominal, carotid or renal artery disease. Given 
the markedly higher risk for cardiovascular events in patients with polyvascular disease, screening of 
EVD should be mandatory in patients with CAD. Furthermore, patients with polyvascular disease 
were less frequently treated with optimal medical therapies [11,21-23].
 
In consistent with these 
reports, statins were less frequently used in patients with polyvascular disease than in patients with 
CAD alone in this study. Further efforts should be directed towards better identification of EVD and 
optimal treatment to reduce the excess risks of CAD patients with concomitant stroke and/or EVD. 
There are several limitations in this study. First, baseline characteristics were markedly 
different between patients with prior stroke and/or EVD, and patients with CAD alone. Second, 
 
screening tests for EVD was left to the discretion of each attending physician. Therefore, the 
proportion of patients with polyvascular disease might be underestimated. Third, EVD included 
those involving various vascular territories. Clinical outcomes after coronary revascularization in 
patients with polyvascular disease might be different according to the vascular territories involved. 
Forth, patients with vascular diseases treated by medication only were excluded from EVD group in 
this study. However, it would be appropriate to evaluate clinically relevant polyvascular disease by 
the definitions of EVD being treated or scheduled for surgical or endovascular interventions. Fifth, 
there was no information about the timing of prior stroke. Finally, causes of cerebral infarction were 
not assessed in this study, and we could not distinguish cardioembolic, atherothrombotic, or lacunar 
infarction for both prior stroke and recurrent stroke.  
In conclusion, clinical outcome after coronary revascularization was worse in patients with 
prior stroke and/or EVD, which was mainly driven by the increased risk for non-coronary 
cardiovascular events. 
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Figure legends 
Fig. 1. 
Cumulative incidence of (A) composite of CV death, MI and stoke and (B) all-cause death. 
CV, cardiovascular; MI, myocardial infarction; CAD, coronary artery disease; EVD, extra-cardiac 
vascular disease. 
Fig. 2. 
Adjusted risk for clinical outcomes in the stroke+CAD, EVD+CAD, and stroke/EVD/CAD groups as 
compared with the CAD alone group. 
CV, cardiovascular; MI, myocardial infarction; CAD, coronary artery disease; EVD, extra-cardiac 
vascular disease; HR, hazard ratio; CI, confidence interval.
Tables 
Table 1 
Baseline characteristics  
     CAD Alone Stroke and CAD EVD and CAD Stroke/EVD/CAD P value 
  (N=12593) (N=1443) (N=974) (N=253)   
(A) Clinical characteristics      
 Age (years) 67.5±11.0 71.9±9.4 71.3±9.2 72.3±7.7 <0.0001 
   Age ≥ 75 years* 29% 42% 42% 43% <0.0001 
 Male* 71% 73% 80% 88% <0.0001 
 BMI 23.8±3.4 23.3±3.5 22.7±3.4 22.6±3.0 <0.0001 
   BMI < 25.0* 68% 72% 78% 84% <0.0001 
 Acute myocardial infarction* 34% 30% 12% 12% <0.0001 
 Hypertension* 81% 87% 84% 89% <0.0001 
 Systolic blood pressure 136±25.0 136±26.4 137±23.9 136±23.8 0.63 
 Diabetes mellitus* 38% 45% 41% 47% <0.0001 
      Insulin therapy 8.2% 12% 12% 13% <0.0001 
 Current smoking* 32% 22% 35% 19% <0.0001 
 Heart failure* 20% 28% 17% 23% <0.0001 
 Shock at presentation 5.4% 7.6% 3.9% 3.2% 0.0003 
 Mitral regurgitation grade 3/4* 3.7% 5.2% 4.5% 4.0% 0.04 
 Ejection fraction 58.5±13.3 56.2±14.0 59.5±13.7 59.4±13.3 <0.0001 
 Prior myocardial infarction* 11% 17% 12% 12% <0.0001 
 Extra-cardiac vascular disease      
    Aortic disease   35% 32% <0.0001 
    Carotid artery disease   12% 29% <0.0001 
    Other peripheral vascular disease   59% 49% <0.0001 
 Multivessel disease 59% 70% 68% 70% <0.0001 
 Target of proximal LAD* 62.0% 62.0% 59.0% 63.0% 0.3 
 Unprotected LMCA* 8.0% 9.3% 11% 13% 0.0002 
 Target of CTO* 15% 17% 18% 19% 0.02 
 Mode of revascularization: CABG* 13% 17% 21% 25% <0.0001 
 eGFR <30, not on dialysis* 3.8% 8.5% 6.1% 8.7% <0.0001 
 Dialysis* 3.4% 4.8% 9.3% 7.5% <0.0001 
 Atrial Fibrillation* 8.9% 16% 10% 17% <0.0001 
 Anemia (Hb < 11 g/dl)* 11% 19% 20% 19% <0.0001 
 Platelet < 100*10
9
/L* 1.5% 1.5% 3.1% 1.6% 0.01 
 COPD* 3.4% 4.7% 3.0% 3.2% 0.07 
 Liver cirrhosis* 2.5% 3.1% 4.1% 2.4% 0.03  
 Malignancy* 8.9% 9.7% 12% 13% 0.004  
(B) Baseline medication      
Medication at hospital discharge      
 Antiplatelet therapy      
   Thienopyridine 85% 83% 80% 78% <0.0001 
       Ticlopidine 90% 91% 92% 90% 0.68 
       Clopidogrel 9.6% 9.2% 8.4% 10%  
   Aspirin 99% 98% 97% 97% <0.0001 
   Cilostazole* 18% 18% 16% 14% 0.24 
 Other medications      
   Statins* 50% 41% 40% 36% <0.0001 
   Beta-blockers* 30% 28% 24% 23% <0.0001 
   ACE-I/ARB* 55% 57% 47% 55% <0.0001 
   Nitrates* 35% 38% 35% 32% 0.06 
   Calcium channel blockers* 40% 48% 53% 56% <0.0001 
   Nicolandil* 26% 27% 22% 26% 0.03 
   Warfarin* 12% 15% 15% 22% <0.0001 
   Proton pump inhibitors* 27% 29% 31% 32% 0.04  
   H2-blockers* 27% 26% 24% 30% 0.03 
Values are expressed as mean ± SD.  
CAD: coronary artery disease; EVD: extra-cardiac vascular disease; BMI: body mass index; LAD: left anterior descending artery; LMCA: 
left main coronary artery disease; CTO: chronic total occlusion; CABG: coronary artery bypass grafting, eGFR: estimated glomerular 
filtration rate; Hb: hemoglobin; COPD: chronic obstructive pulmonary disease; ACE-: angiotensin converting enzyme inhibitors; ARB: 
angiotensin II receptor blockers.  





Cumulative 3-year incidence of events     
  CAD Alone Stroke and CAD EVD and CAD Stroke/EVD/CAD P value 
 (N=12593)  (N=1443)  (N=974)  (N=253)  
  Cumulative Incidence Cumulative Incidence Cumulative Incidence Cumulative Incidence   
 MACE 11.2% 19.9% 18.5% 20.1% <0.0001 
 All-cause death 9.0% 16.9% 16.1% 16.0% <0.0001 
 Cardiovascular death 5.9% 11.4% 10.4% 10.7% <0.0001 
 Non-cardiovascular death 3.3% 6.3% 6.3% 6.0% <0.0001 
 Myocardial infarction 3.2% 3.5% 4.6% 3.2% 0.34 
 Stroke 3.9% 9.2% 7.9% 9.6% <0.0001 
   Ischemic stroke 3.0% 7.9% 6.0% 6.4% <0.0001 
   Hemorrhagic stroke 0.9% 1.4% 2.1% 3.9% <0.0001 
 Any coronary revascularization 29.4% 27.0% 30.2% 23.3% 0.02 
Cumulative incidence was estimated by the Kaplan-Meier method. 




Causes of death during follow-up 
   
  
  CAD Alone Stroke and CAD EVD and CAD Stroke/EVD/CAD P value 
  (N=12593) (N=1443) (N=974) (N=253)   
 Cardiac death 60.8% 56.0% 47.0% 52.8% 0.02 
    Acute myocardial infarction 21.3% 16.3% 10.5% 11.1% 
     Heart failure 10.4% 12.0% 9.0% 16.7% 
     Documented VF/ sudden death 7.8% 7.7% 12.7% 8.3% 
     Other cardiac death 21.3% 20.1% 14.9% 16.7% 
  Vascular death 6.1% 12.9% 17.9% 13.9% <0.0001 
    Stroke 4.4% 5.7% 9.7% 5.6% 
       Ischemic stroke 1.7% 3.4% 3.0% 0% 
       Hemorrhagic stroke 2.6% 2.4% 6.7% 5.6% 
     Other vascular death 1.7% 7.2% 8.2% 8.3% 
  Non-cardiovascular death 33.1% 31.1% 35.1% 33.3% 0.89 
   Malignancy 15.4% 9.1% 14.9% 11.1%  
   Infection 9.7% 11.0% 9.0% 11.1%  
   Other non-cardiovascular death 8.0% 11.0% 11.2% 11.1%   




































0 365 730 1095
Interval 0 day 30 days 1 year 2 years 3 years
CAD Alone
N of patients with event 478 897 1110 1257
N of patients at risk 12593  11981 11115 8609 4631
Cumulative Incidence 3.8% 7.2% 9.2% 11.2%
Stroke+CAD
N of patients with event 79 178 224 251
N of patients at risk 1443 1346 1171 855 451
Cumulative Incidence 5.5% 12.7% 16.4% 19.9%
EVD+CAD
N of patients with event 44 110 138 157
N of patients at risk 974 918 804 605 310
Cumulative Incidence 4.5% 11.6% 14.8% 18.5%
Stroke/EVD/CAD
N of patients with event 8 29 41 46
N of patients at risk 253 242 210 156 87



















































Interval 0 day 30 days 1 year 2 years 3 years
CAD Alone
N of patients with event 252 617 828 987
N of patients at risk 12593 12210 11509 9005 4900
Cumulative Incidence 2.0% 5.0% 6.8% 9.0%
Stroke+CAD
N of patients with event 51 127 179 209
N of patients at risk 1443 1375 1237 923 493
Cumulative Incidence 3.5% 9.0% 13.2% 16.9%
EVD+CAD
N of patients with event 16 77 110 134
N of patients at risk 974 946 849 649 336
Cumulative Incidence 1.7% 8.1% 11.9% 16.1%
Stroke/EVD/CAD
N of patients with event 4 21 32 36
N of patients at risk 253 246 222 167 92




Adjusted HR (95% CI) P





























0 0.5 1.0 1.5 2.0 2.5 3.0 3.5
1.34 (1.17-1.54)
1.56 (1.32-1.84) 
1.66 (1.24-2.23)
<0.0001
<0.0001
0.0007
1.22 (1.05-1.42)
1.54 (1.28-1.84) 
1.77 (1.29-2.43)
1.17 (0.97-1.40)
1.61 (1.28-2.02) 
1.77 (1.18-2.64)
1.31 (1.01-1.70)
1.42 (1.05-1.92) 
1.69 (1.01-2.82)
1.06 (0.78-1.45)
1.29 (0.91-1.83) 
1.01 (0.48-2.16)
1.85 (1.49-2.29)
1.86 (1.42-2.43) 
2.13 (1.39-3.27)
0.92 (0.82-1.03)
1.10 (0.97-1.25) 
0.89 (0.68-1.17)
0.01
<0.0001
0.0004
0.10
<0.0001
0.005
0.04
0.02
0.046
0.71
0.15
0.97
<0.0001
<0.0001
<0.0001
0.15
0.15
0.41
